Hematologic Malignancies: New Therapies and the Evolving Role of Transplant 2015

Chicago, IL US
April 10, 2015 to April 11, 2015

This two-day course is presented by Mayo faculty discussing the role of blood and marrow transplantation (BMT) for hematologic malignancies and solid tumors in an era when new therapies for these diseases are becoming available. The course is for hematology-oncology physicians, allied health practitioners, and nurses and helps increase their understanding of when patients should be referred for BMT in the course of their disease.

Registration Fee
Physician/Scientist Course Registration      $400.00
Allied Health/Student Course Registration    $325.00

Credit Information
Mayo Clinic College of Medicine designates this live activity for a maximum of 11 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hotel Information
The Westin Chicago River North  
320 North Dearborn Street
Chicago, IL 60654

Special room rates are available until the block is sold out or March 9, 2015, whichever comes first. The discounted rate is $179 plus tax. 

To ensure accommodations at the discounted rate, please make your reservations directly with the hotel by calling 888-627-8359 (toll-free) by March 9, 2015. Please indicate that you are a participant of the Mayo Clinic Hematologic Malignancies Course when making your reservation.

 

Learning Objectives

Learning Objectives

Upon conclusion of this program, participants should be able to:

  • Utilize patient stratification strategies to determine the most appropriate therapies for patients with hematologic malignancies
  • Integrate the blood & marrow transplantation (BMT) process into current treatment strategies when clinically indicated to improve patient outcomes
  • Describe new innovations and limitations in stem cell mobilization
  • Explain how different stem cell sources can be utilized to optimize BMT outcomes for patients
  • Differentiate the advantages & disadvantages of autologous vs. allogeneic transplantation
  • Recognize patient- and treatment- related factors affecting immune reconstitution following BMT
  • Demonstrate knowledge of appropriate care of long-term survivors of BMT
  • Review the use of targeted therapies in metastatic renal cell carcinoma and other malignancies
  • Describe relevant pharmacologic issues related to the polypharmacy of patients in the post-BMT period

Attendance at this Mayo course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.

Additional Information

Course summary
Available credit: 
  • 11.00 AMA PRA Category 1 Credit
Event starts: 
04/10/2015 - 6:00am
Event ends: 
04/11/2015 - 2:00pm
Rating: 
0
Westin Chicago River
320 N. Dearborn Street
Chicago, IL 60654
United States

Faculty

Course Directors

  • William J. Hogan
  • Mark R. Litzow

Guest Faculty

  • Claudio Brunstein, M.D., Ph.D.
    University of Minnesota Medical School
    Minneapolis, MN
  • Hillard M. Lazarus, M.D.
    University Hospitals Case Medical Center
    Cleveland, Ohio

Mayo Clinic Faculty

  • Francis K. Buadi, M.D.
  • Brian A. Costello, M.D.
  • Veena D. Fauble, M.D.
  • James M. Foran, M.D.
  • Paul Haluska, Jr., M.D., Ph.D.
  • Shahrukh K. Hashmi, M.D.
  • Patrick B. Johnston, M.D., Ph.D.
  • Saad J. Kenderian, M.B., Ch.B.
  • Shaji Kumar, M.D.
  • Jose Leis, M.D.
  • Julianna A. Merten, Pharm.D., R.Ph.
  • Ivana N. Micallef, M.D.
  • Timothy J. Nelson, M.D., Ph.D.
  • Mrinal Patnaik, M.B.B.S.
  • Craig Reeder, M.D.

Faculty Disclosure

  • As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Available Credit

  • 11.00 AMA PRA Category 1 Credit
Please login or register to take this course.